Overview

Metformin Hydrochloride Sustained-release Tablets () in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

Status:
RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is1. Compare the differences in the changes of glycated hemoglobin after 24 weeks of treatment between the new metformin sustained-release tablets () group and the metformin ordinary tablets group. 2\. Compare the differences in the changes of fasting blood glucose, gastrointestinal adverse reactions of the drug and compliance after 24 weeks of treatment between the new metformin sustained-release tablets () group and the metformin ordinary tablets group.

Phase:

PHASE4

Details

Lead Sponsor:

China National Center for Cardiovascular Diseases

Treatments:

Metformin